Entrectinib—A SARS-CoV-2 Inhibitor in Human Lung Tissue (HLT) Cells

Peralta-Garcia, Alejandro; Torrens-Fontanals, Mariona; Stepniewski, Tomasz Maciej; Grau Exposito, Judit; Perea Pérez, David; Ayinampudi, Vikram; Buzón Gómez, María José; Genesca Ferrer, Meritxell

View

Entrectinib—A SARS-CoV-2 Inhibitor in Human Lung Tissue (HLT) Cells, 2021 (2.327Mb)

Date

2021-12

Author

Peralta-Garcia, Alejandro

Torrens-Fontanals, Mariona

Stepniewski, Tomasz Maciej

Grau Exposito, Judit

Perea Pérez, David

Ayinampudi, Vikram

Buzón Gómez, María José

Genesca Ferrer, Meritxell

Show full item record

Abstract

Since the start of the COVID-19 outbreak, pharmaceutical companies and research groups have focused on the development of vaccines and antiviral drugs against SARS-CoV-2. Here, we apply a drug repurposing strategy to identify drug candidates that are able to block the entrance of the virus into human cells. By combining virtual screening with in vitro pseudovirus assays and antiviral assays in Human Lung Tissue (HLT) cells, we identify entrectinib as a potential antiviral drug.

Keywords

COVID-19; Drug repurposing; Viral cell entry assays

Bibliographic citation

Peralta-Garcia A, Torrens-Fontanals M, Stepniewski TM, Grau-Expósito J, Perea D, Ayinampudi V, et al. Entrectinib—A SARS-CoV-2 Inhibitor in Human Lung Tissue (HLT) Cells. Int J Mol Sci. 2021 Dec;22(24):13592.